Surgical treatment for presbyopia owned by Refocus Group, Inc., and partnered with CIBA Vision for distribution. PresVIEW has received European CE Mark approval for the PresVIEW Scleral Incision System in August 2003. The company has re-engineered the system for its PresVIEW Scleral Spacing Procedure, which surgically treats presbyopia, primary open angle glaucoma and ocular hypertension. The updated procedure incorporates automated components to simplify and enhance placement of Refocus Group's PresVIEW scleral implants, resulting in greater reproducibility of the procedure by clinicians. Refocus Group's strategic partner, CIBA Vision, plans a commercial launch of the PresVIEW Scleral Spacing Procedure in selected European markets by the end of 2003. Refocus Group also aims to begin FDA Phase II clinical trials of the procedure for presbyopia in late 2003, subject to FDA approval.